gc012f
gracell biotechnologies
['gc012f ', 'dlbcl', '$grcl']
2. $grcl +18.5% (6x avg. vol), +225% since apr low, data at #eha2023 for gc012f car-t showed 100% overall response rate at 3mo. and 66.7% 6-mo complete response in 9 r/r dlbcl patients, $320mil mcap, $186mil cash, funded into 2h 24, med. $ $12.57 (+165%) 
Biotech stock analyst. Editor of Biotech Millionaire at Mauldin Economics. Tweets and opinions are not investment advice.